Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 14 July 2026

₹4,951.1 ↑ 45.41% (1Y)

🎯 Key Takeaways

Torrent Pharmaceuticals is in a growth phase driven by strategic acquisitions and expanding international markets, particularly in Brazil and the US. The company has transitioned from stable domestic performance to accelerated growth post-acquisition of JB Pharma, supported by strong operational margins and consistent profitability.
Revenue declined 2.8% QoQ to ₹2,809 in Q3FY25.
⚠️ Integration risk from the JB Pharma acquisition, as highlighted by management in the context of 'exceptional items' and non-comparable figures in FY26

Market Cap

₹1.49 L Cr

P/E Ratio

80.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About TORNTPHARM 📊 Interactive Charts

📖 The Story

Torrent Pharmaceuticals is in a growth phase driven by strategic acquisitions and expanding international markets, particularly in Brazil and the US. The company has transitioned from stable domestic performance to accelerated growth post-acquisition of JB Pharma, supported by strong operational margins and consistent profitability. It is now a mid-sized global player with a focus on scale and capital efficiency.

📰 What's Happening

The company's recent trajectory is defined by the acquisition of JB Pharma, finalized in January 2026, which contributed to a 21% YoY revenue growth in FY26, reaching ₹13,980 crores. Consolidated net profit stood at ₹2,138 crores, with Q4 revenue surging 42% YoY to ₹4,197 crores. Management highlighted integration progress and market traction in international markets during the FY26 results announcement on May 22, 2026. The 53rd AGM on June 23, 2026 approved financial statements and declared dividends, reaffirming a shareholder-friendly capital return policy. Additionally, a ₹5,000 crore Qualified Institutional Placement (QIP) was announced to fund future growth initiatives.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	2,491	2,591	2,660	2,732	2,745	2,859	2,889	2,809
Operating Profit	736	825	851	924	914	928	923	947
OPM %	29.2%	30.5%	31.0%	31.8%	32.2%	31.6%	32.5%	32.5%
Net Profit	287	378	386	443	449	457	453	503
EPS	₹8.48	₹11.18	₹11.39	₹13.10	₹13.27	₹13.51	₹13.37	₹14.88

Torrent Pharma has demonstrated consistent top-line stability and improving profitability over the past eight quarters, with operating margins holding firm around 32% despite macroeconomic pressures. The sharp acceleration in FY26 revenue and profit is directly linked to the JB Pharma acquisition, which added scale and geographic diversification. Sequential growth in Q3FY25 (₹2,809 crores revenue, ₹503 crores net profit) reflects resilience in core domestic formulations, while OPM expansion to 32.54% indicates operating leverage. The company is now scaling rapidly on the back of international demand and integration momentum.

🔮 Management Outlook & What's Next

In its FY26 results announcement, management expressed confidence in sustained growth, citing strong performance in Brazil and the US markets as key drivers. The company proposed a final dividend of ₹9 per share (180% payout ratio) and plans to raise ₹5,000 crores via QIP to strengthen balance sheet and fund strategic initiatives. Management emphasized that the acquisition has unlocked cross-selling opportunities and enhanced global footprint, with no major integration roadblocks reported. The unmodified auditor's opinion on consolidated financials reinforces transparency and compliance with SEBI and Ind AS standards.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB CIPLA DRREDDY LUPIN

⚠️ Risk Factors

1. Integration risk from the JB Pharma acquisition, as highlighted by management in the context of 'exceptional items' and non-comparable figures in FY26 results. 2. Geographic concentration risk in Brazil and US markets, which drove 42% YoY growth in Q4 but may face regulatory or competitive pressures. 3. High valuation multiples (P/E of 80.1) priced in future growth, making the stock vulnerable to earnings miss or macro headwinds. 4. Regulatory scrutiny in international markets, particularly in the US and Brazil, where compliance and pricing pressures are increasing.

📋 Recent Filings

🧠 Analyst's Read

Torrent Pharmaceuticals is executing a clear growth strategy through acquisition and international expansion, supported by strong margins and consistent profitability. Investors should monitor the pace of integration of JB Pharma, sustainability of growth in Brazil and the US, and the effective use of the ₹5,000 crore QIP proceeds. While fundamentals are sound, the elevated valuation demands near-perfect execution. The next key catalyst will be quarterly updates on international performance and progress on strategic initiatives post-acquisition.

Based on filing content and financial data. Not a recommendation.

✨ Deep Dive with AI on TORNTPHARM

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-14.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track TORNTPHARM — Free

Free account · 2 AI queries/day